Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P60709
UPID:
ACTB_HUMAN
Alternative names:
Beta-actin
Alternative UPACC:
P60709; P02570; P70514; P99021; Q11211; Q64316; Q75MN2; Q96B34; Q96HG5
Background:
Actin, cytoplasmic 1, also known as Beta-actin, is a pivotal protein in cell structure and motility. It exists in monomeric (G-actin) and polymeric (F-actin) forms, essential for cell motility, contraction, and the integrity of the cytoskeleton. Its presence in the nucleus also influences gene transcription and DNA repair. Actin forms the backbone of the ACTR1A/ACTB filament, crucial for the dynactin complex and dynein motor function.
Therapeutic significance:
Actin, cytoplasmic 1, is implicated in juvenile-onset dystonia and Baraitser-Winter syndrome 1, diseases characterized by developmental malformations and neurological symptoms. Understanding the role of Actin, cytoplasmic 1, could open doors to potential therapeutic strategies for these conditions.